Who
Stephen Uden
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Rallybio; Exec VP, Research & Developmen, Neurogen.
In numbers
- Trades disclosed
- 17
- Buys
- 2
- Sells
- 0
- Bought
- $99K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Dec 2006
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code M | $137K22,456 at $6.08 | filing |
| 6 Oct 2026filed 8 Oct 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code M | —22,456 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —453,700 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —216,000 at $0.00 | filing |
| 6 Feb 2023filed 6 Feb 2023 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —214,000 at $0.00 | filing |
| 7 Feb 2022filed 9 Feb 2022 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 13 Jan 2022filed 14 Jan 2022 | RLYB RallybioBiotechnology | SEC FORM 4 Bought | $38K4,193 at $9.06 | filing |
| 13 Jan 2022filed 14 Jan 2022 | RLYB RallybioBiotechnology | SEC FORM 4 Bought | $7,763807 at $9.62 | filing |
| 12 Jan 2022filed 14 Jan 2022 | RLYB RallybioBiotechnology | SEC FORM 4 Bought | $53K5,000 at $10.55 | filing |
| 28 Jul 2021filed 14 Jan 2022 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code J | —4,820,000 | filing |
| 28 Jul 2021filed 14 Jan 2022 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code J | —150,000 | filing |
| 28 Jul 2021filed 14 Jan 2022 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code J | —100,000 | filing |
| 28 Jul 2021filed 14 Jan 2022 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code J | —107,891 | filing |
| 28 Jul 2021filed 14 Jan 2022 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 28 Jul 2021filed 14 Jan 2022 | RLYB RallybioBiotechnology | SEC FORM 4 Code J | —709,127 | filing |
| 17 Jan 2007filed 19 Jan 2007 | Neurogenoption or derivative | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 15 Dec 2006filed 19 Dec 2006 | Neurogenoption or derivative | SEC FORM 4 Code A | —36,400 at $0.00 | filing |
News
Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)RLYB · dailypolitical.com · 14 Oct 2026Financial Analysis: NewAmsterdam Pharma (NASDAQ:NAMS) versus Rallybio (NASDAQ:RLYB)RLYB · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Stephen Uden; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.